AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company focused on botulinum toxin-based therapeutics, which became a publicly traded entity following its business combination with Priveterra Acquisition Corp, a blank-check company sponsored by Priveterra Acquisition LLC that completed its IPO in 2022. AEON filed an S-1 registration statement on July 8, 2026 (accession no. 0001104659-26-081860), a step that typically accompanies post-merger share registration for the healthcare sector issuer. The company operates in the specialty biopharma space and continues to pursue regulatory and clinical milestones as a public company. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on AEON and hundreds of other transactions.